MedTrace Logo

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

NCT05823701 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-04-21

No results posted yet for this study

Summary

To evaluate the efficacy and safety of CAGM regimen in R/R DLBCL patients and to provide a safe and more effective approach for R/R DLBCL patients.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Chidamide

20 mg (4 capsules), d1, d4, d8, d11 orally per cycle

DRUG

Azacitidine

100mg d1- d5 subcutaneous injection per cycle

BIOLOGICAL

obinutuzumab

1000mg d4 intravenous infusion per cycle

DRUG

Liposomal mitoxantrone

20mg/m2 d5 intravenous infusion per cycle

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05823701 on ClinicalTrials.gov